Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M20,137Revenue $M816Net Margin (%)8.8Altman Z-Score54.5
Enterprise Value $M19,250EPS $0.9Operating Margin %13.2Piotroski F-Score5
P/E(ttm)292Beneish M-Score-0.6Pre-tax Margin (%)13.3Higher ROA y-yN
Price/Book22.510-y EBITDA Growth Rate %--Quick Ratio5.3Cash flow > EarningsY
Price/Sales25.15-y EBITDA Growth Rate %--Current Ratio5.5Lower Leverage y-yY
Price/Free Cash Flow196y-y EBITDA Growth Rate %-35.7ROA % (ttm)7.6Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)9.6Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M76.8ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with PCYC

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
PCYCMario Gabelli 2015-03-31 Buy 0.04%$119.85 - $258.35
($193.06)
$ 261.2535%New holding27,750
PCYCJoel Greenblatt 2015-03-31 Sold Out -0.0026%$119.85 - $258.35
($193.06)
$ 261.2535%Sold Out0
PCYCKen Fisher 2015-03-31 Sold Out -0.0008%$119.85 - $258.35
($193.06)
$ 261.2535%Sold Out0
PCYCJoel Greenblatt 2014-12-31 Buy $103.79 - $141.55
($128.16)
$ 261.25104%New holding2,619
PCYCJoel Greenblatt 2014-09-30 Sold Out -0.09%$91.5 - $127.81
($114.49)
$ 261.25128%Sold Out0
PCYCKen Fisher 2014-09-30 Reduce$91.5 - $127.81
($114.49)
$ 261.25128%Reduce 36.57%3,244
PCYCJoel Greenblatt 2014-06-30 Add0.08%$85.85 - $107.42
($93.89)
$ 261.25178%Add 724.62%79,089
PCYCMariko Gordon 2014-06-30 Sold Out -0.04%$85.85 - $107.42
($93.89)
$ 261.25178%Sold Out0
PCYCKen Fisher 2014-06-30 Buy $85.85 - $107.42
($93.89)
$ 261.25178%New holding5,114
PCYCMariko Gordon 2014-03-31 Add0.02%$100.49 - $151.61
($129.71)
$ 261.25101%Add 112.41%9,295
PCYCJoel Greenblatt 2014-03-31 Buy 0.01%$100.49 - $151.61
($129.71)
$ 261.25101%New holding9,591
PCYCMariko Gordon 2013-12-31 Add0.01%$99.28 - $139.59
($121.32)
$ 261.25115%Add 130.07%4,376
PCYCMariko Gordon 2013-09-30 Buy 0.01%$84.5 - $132.49
($110.93)
$ 261.25136%New holding1,902
PCYCJoel Greenblatt 2013-03-31 Sold Out -0.14%$57.78 - $94.2
($77.47)
$ 261.25237%Sold Out0
PCYCJoel Greenblatt 2012-12-31 Buy 0.14%$47.87 - $69.78
($58.72)
$ 261.25345%New holding41,832
PCYCGeorge Soros 2012-06-30 Sold Out -0.04%$25.72 - $53.44
($32.62)
$ 261.25701%Sold Out0
PCYCGeorge Soros 2012-03-31 Buy 0.04%$14.99 - $28.68
($20.91)
$ 261.251149%New holding100,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

PCYC is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


PCYC: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Soni Manmeet SinghCFO 2015-03-13Sell27,514$254.242.76view
Tan HeowChief Quality&Tech Operations 2015-03-12Sell1,000$254.512.65view
Zanganeh MakyCOO 2015-03-11Sell30,000$254.112.81view
Zanganeh MakyCOO 2015-03-11Sell30,000$254.112.81view
Fardis MariaChief of Oncology Ops & Allian 2014-11-13Sell3,000$141.384.89view
Soni Manmeet SinghCFO 2014-11-13Sell1,000$141.4484.71view
Zanganeh MakyCOO 2014-11-12Sell30,482$134.6993.96view
Love Richard BGeneral Counsel 2014-11-10Sell1,500$133.8795.15view
Fardis MariaChief of Oncology Ops & Allian 2014-11-07Sell5,000$134.594.24view
Zanganeh MakyCOO 2014-09-04Sell12,000$121.75114.58view

Quarterly/Annual Reports about PCYC:

News about PCYC:

Articles On GuruFocus.com
Eric Mindich Increases His Most Valuable Stake in First Quarter Jun 12 2015 
AbbVie Floats Mega-Bond Deal For Acquisition Funding May 08 2015 
Wall Street’s Best and Worst Calls of the First Quarter 2015 May 07 2015 
Pharmacyclics Posts A Mixed First Quarter Ahead Of Being Acquired By AbbVie May 07 2015 
AbbVie Focusing On Diversification Routes To Put Higher Sales Numbers On The Board Apr 24 2015 
Weekly Insider Sells Highlight: PCYC, DIS, AZO, SCI Mar 17 2015 
AbbVie Strikes The Biggest Deal For Treatment Of Cancer Mar 10 2015 
AbbVie To Acquire Biopharmaceutical Firm Pharmacyclics Mar 06 2015 
own Mar 02 2015 
Weekly 52-Week Highs Highlight: DG, AGN, ADSK, AVGO, PCYC Feb 22 2015 

More From Other Websites
AbbVie (ABBV) Earnings Report: Q2 2015 Conference Call Transcript Jul 24 2015
Chi-Med Arthritis Drug Spurs Interest From Potential Partners Jun 18 2015
Eric Mindich Increases His Most Valuable Stake in First Quarter Jun 12 2015
Ibrutinib (IMBRUVICA®) Phase Ib/II Data Show Promise in Patients with Chronic... May 31 2015
Phase III HELIOS Study Results Show Ibrutinib (IMBRUVICA®) Combination Therapy Significantly... May 30 2015
ABBVIE INC. Financials May 29 2015
Ibrutinib (IMBRUVICA®) in Combination with Anti-PD-L1 Antibody (MEDI4736) Study Commences for... May 28 2015
AbbVie Accelerates Share Buybacks May 27 2015
Ambarella Leads 3 Top Stocks Bucking The Sell-Off May 26 2015
Pharmacyclics' Imbruvica Gets CHMP's Nod for Full Approval - Analyst Blog May 26 2015
Jim Cramer -- Here's Why I'm Buy, Buy, Buying J&J and Selling Merck May 26 2015
Abbvie completes $21 billion buyout of Pharmacyclics May 26 2015
Abbvie completes $21 billion buyout of Pharmacyclics May 26 2015
PHARMACYCLICS INC Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Notice of... May 26 2015
AbbVie Completes Acquisition of Pharmacyclics May 26 2015
The Most Loved Biotechs of Big Hedge Funds May 23 2015
European Medicines Agency Issues Positive Opinion, Recommends Full Approval of IMBRUVICA®... May 22 2015
Abbvie specifies breakdown of $21 billion Pharmacyclics deal May 21 2015
Abbvie specifies breakdown of $21 billion Pharmacyclics deal May 21 2015
AbbVie Announces Offer Consideration for Acquisition of Pharmacyclics May 21 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK